# Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

> **NCT00119626** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1700 (—)

## Conditions studied

- Cerebral Stroke
- Ischemic Attack, Transient

## Interventions

- **DRUG:** NXY-059

## Key facts

- **NCT ID:** NCT00119626
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2005-02
- **Final completion:** 2005-02
- **Target enrollment:** 1700 (—)
- **Last updated:** 2010-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00119626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00119626, "Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00119626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*